2012-09-18 08:08:27 - Recently published research from Global Markets Direct, "Bladder Cancer - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Bladder Cancer - Pipeline Review, H2 2012', provides an overview of the Bladder Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. 'Bladder Cancer - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463828_bladder_cancer_pipeline_review_h2_201 ..


Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Bladder Cancer.
* A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Bladder Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bladder Cancer Therapeutic Products under Development, Key Players in Bladder Cancer Therapeutics, Bladder Cancer Pipeline Overview, Bladder Cancer Pipeline, Bladder Cancer Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bladder Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Bladder Cancer
Bladder Cancer Therapeutics under Development by Companies
Bladder Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bladder Cancer Therapeutics - Products under Development by Companies
Bladder Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Bladder Cancer Therapeutics Development
Shionogi & Co., Ltd.
Sanofi-Aventis
Eli Lilly and Company
Viralytics Ltd.
Bioniche Life Sciences, Inc.
Inovio Biomedical Corporation
Bavarian Nordic A/S
Genta Incorporated
MDRNA, Inc.
Celgene Corporation
Advaxis, Inc.
Celldex Therapeutics, Inc.
AEterna Zentaris Inc.
Cleveland BioLabs, Inc.
Oncolytics Biotech Inc.
Allos Therapeutics, Inc
Oncogenex Pharmaceuticals, Inc.
Dendreon Corporation
Sanochemia Pharmazeutika AG
OncoTherapy Science, Inc.
PharmaGap Inc.
Quest PharmaTech Inc.
Spectrum Pharmaceuticals, Inc.
Acceleron Pharma, Inc.
Med Discovery SA
Altor BioScience Corporation
Telormedix SA
Gene Signal International SA.
Heat Biologics, Inc.
MacroGenics, Inc.
Stemline Therapeutics, Inc.
BioCancell Therapeutics, Inc.
AndroScience Corporation
Collgard Biopharmaceuticals Ltd.
PharmaMar, S.A.
TRACON Pharmaceuticals, Inc.
Targa Therapeutics Corp.
Cytavis Biopharma GmbH
EyeGene, Inc.
Bladder Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEZS-108 - Drug Profile
Icrucumab - Drug Profile
Tesetaxel - Drug Profile
OGX-427 - Drug Profile
Sotatercept - Drug Profile
MDRG01 - Drug Profile
MDP01 - Drug Profile
Abraxane - Drug Profile
Urocidin - Drug Profile
SL-601 - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463828&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.